Key result
ACE2-mediated entry links ACE inhibitors and ARBs to potential COVID-19 susceptibility and severity risks.
he prevalence of coronavirus disease 2019 (COVID-19) has posed a great threat to people's health worldwide, bringing a great challenges to the public healthcare systems. A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses severe acute respiratory syndrome coronavirus (SARS-CoV) receptor angiotensin-converting enzyme 2 (ACE2) for host cell entry. 1 ACE2 expression was previously found to correlate with susceptibility to SARS-CoV infection in vitro.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2020) conducted a review in Coronavirus Disease 2019 (COVID-19). Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers was evaluated. SARS-CoV-2 uses the ACE2 receptor for host cell entry, suggesting a potential influence of ACE inhibitors and ARBs on COVID-19 susceptibility and severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: